Comparison · NCT05822830-sae
15 mg or MTD - Tirzepatide vs 2.4 mg or MTD - Semaglutide: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. 15 mg or MTD - Tirzepatide vs 2.4 mg or MTD - Semaglutide: serious adverse events. Trial comparisons, record NCT05822830-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT05822830-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0481 | 0.0307 | 0.0748 | wilson | |
| Risk in group 2 | 0.0346 | 0.0203 | 0.0582 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0136 | -0.0159 | 0.0438 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.39 | 0.692 | 2.8 | log | |
| Odds ratio, group 1 over group 2 | 1.41 | 0.682 | 2.92 | log | |
| Number needed to harm, for one more participant with a serious adverse event on 15 mg or MTD - Tirzepatide than on 2.4 mg or MTD - Semaglutide | 73.8 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | 15 mg or MTD - Tirzepatide | Participants received a starting dose of 2.5 mg tirzepatide administered SC QW for 4 weeks, then the dose was increased by 2.5 mg every 4 weeks (2.5 to 5 to 7.5 to 10 to 12.5 to 15 mg) up to 15 mg QW or MTD (10 mg or 15 mg) until Week 72. | 18 | 374 | EG000 |
| Group 2 | 2.4 mg or MTD - Semaglutide | Participants received a starting dose of 0.25 mg semaglutide administered SC QW for 4 weeks, then the dose was increased every 4 weeks (0.25 to 0.5 to 1.0 to 1.7 to 2.4 mg) up to 2.4 mg QW or MTD (1.7 mg or 2.4 mg) until Week 72. | 13 | 376 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Baseline Up To 72 Weeks
Source ClinicalTrials.gov
Trial
- Title
- A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities
- NCT number
- NCT05822830
- Phases
- PHASE3
- Conditions
- Obesity, Overweight
- Interventions
- Tirzepatide, Semaglutide
- Lead sponsor
- Eli Lilly and Company
- Results first posted
- 2025-11-26
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT05822830?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT05822830-sae